 |
| BIOC, INC. |
The final week of February left my stock portfolio with a less than impressive impact. I purchased BIOC on February 25th based on a break through within the companies studies. Biocept found that it's blood-based diagnostic OncoCEE-BR, was used to determine hormonal status of metallic breast cancer patients in a prospective study at Columbia University in New York. This study caused BIOC to increase nearly 100%. I purchased 5554 shares of the stock at $4.52, which was too late. I purchased the stock too long after the major increase. Over the next 2 days it continued to drop below $3. Once the stock dropped to $2.75 my holdings automatically sold due to a stop limit I had on the order. In total the impact on BIOC decreased my total capital gains by $9,830.58.
No comments:
Post a Comment